Skip to content

Author

Mohammad Alzoubi

We have 2 of 3 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Anthracycline-free versus anthracycline-based neoadjuvant therapy in HER2-positive breast cancer: A Propensity score-matched real-world study.

BACKGROUND Anthracycline-free TCHP and anthracycline-based AC-THP are both used as neoadjuvant dual anti-HER2 regimens for HER2-positive breast cancer, but direct comparisons accounting for HER2 immunohistochemistry (IHC) intensity are lacking. Because IHC 3+ tumors respond substantially better to dual blockade, any be...

B. Sharaf, F. Tamimi, Mohammad Alzoubi et al. · 0 citations
Open access Sep 2026

Pathological Complete Response and Safety of Neoadjuvant Pembrolizumab-Based Chemoimmunotherapy in Triple-Negative and Hormone Receptor-Low Breast Cancer: A Real-World Cohort Study

In this real-world Middle Eastern cohort, pembrolizumab-based chemoimmunotherapy achieved pCR rates consistent with pivotal trial data, and Grade 3 histology, pathogenic germline mutation, and age younger than 40 years were independently associated with pCR.

B. Sharaf, T. Al-Batsh, Suhaib Khater et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.